Animal-Free TNF-alpha/TNFSF2 Protein, Human (His)

TNF-α/TNFSF2 protein is a macrophage-secreted cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR, inducing tumor cell death and acting as a pyrogen. It is associated with cachexia and stimulates cell proliferation and differentiation. Animal-Free TNF-alpha/TNFSF2 Protein, Human (His) is the recombinant human-derived animal-FreeTNF-alpha/TNFSF2 protein, expressed by E. coli , with C-His labeled tag. This product is for cell culture use only.

The TNF-alpha/TNFSF2 Protein, a cytokine, binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR, primarily secreted by macrophages with the capability to induce cell death in specific tumor cell lines. Acting as a potent pyrogen, it causes fever through direct action or by stimulating interleukin-1 secretion and is implicated in the induction of cachexia. Furthermore, under specific conditions, TNF-alpha can stimulate cell proliferation and induce cell differentiation. Notably, in individuals with rheumatoid arthritis, it impairs regulatory T-cells (Treg) function via FOXP3 dephosphorylation, up-regulating the expression of protein phosphatase 1 (PP1) that dephosphorylates the key 'Ser-418' residue of FOXP3, rendering Treg cells functionally defective. Additionally, TNF-alpha is a key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line. It induces insulin resistance in adipocytes by inhibiting insulin-induced IRS1 tyrosine phosphorylation and glucose uptake, leading to GKAP42 protein degradation and TNF-induced insulin resistance. Furthermore, it plays a role in angiogenesis by synergistically inducing VEGF production with IL1B and IL6, and it promotes osteoclastogenesis, contributing to bone resorption. Lastly, the TNF intracellular domain (ICD) form induces IL12 production in dendritic cells, highlighting its diverse impact across various physiological processes.

The ED₅₀ is <0.1 ng/mL as measure by its ability to induce cytotoxicity in L929 cells in the presence of actinomycin D, corresponding to a specific activity of recombinant human TNF alpha is approximately >1 x 10⁷ IU/mg

Human

E. coli

C-6*His

P01375 (V77-L233)

7124  [NCBI]

Full Length of TNF soluble form

VRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL

Approximately 17 kDa, based on SDS-PAGE under reducing conditions.

≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 8.0, trehalose.

<0.1 EU per 1 μg of the protein by the LAL method.

It is recommended to reconstitute to a concentration of 100-200 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.